Lupin is a BUY at CMP@1470 with SL@1420 for a target of TP@1600
Lupin gets USFDA nod to market pain relief, colonoscopy drugs and also gets FDA approval for generic Percocet tablets .
Lupin recently received FDA approval for generic Suprep Bowel Prep Kit and Suprep kit approval It may add 5% to Lupin’s EPS for FY18 earnings.
In addition the pharma major’s Goa facility has been cleared by the US FDA.
Lupin Result: Revenue grew 26% YoY to INR 44.8b Gross margin was stable QoQ at 71.0%. EBITDA rose 27% YoY to INR 12.2b with margin of 27% . EBITDA margin improvement was primarily driven by strong growth in US sales (+53% YoY, +8% QoQ; despite R&D as % of sales at 12.9%) and forex gain of INR 270m. PAT of INR 6.3b was impacted by 1% due to a high tax rate of 39%.
Lupin is a BUY at CMP@1470 with SL@1420 for a target of TP@1600
Lupin gets USFDA nod to market pain relief, colonoscopy drugs and also gets FDA approval for generic Percocet tablets .
Lupin recently received FDA approval for generic Suprep Bowel Prep Kit and Suprep kit approval It may add 5% to Lupin’s EPS for FY18 earnings.
In addition the pharma major’s Goa facility has been cleared by the US FDA.
Lupin Result: Revenue grew 26% YoY to INR 44.8b Gross margin was stable QoQ at 71.0%. EBITDA rose 27% YoY to INR 12.2b with margin of 27% . EBITDA margin improvement was primarily driven by strong growth in US sales (+53% YoY, +8% QoQ; despite R&D as % of sales at 12.9%) and forex gain of INR 270m. PAT of INR 6.3b was impacted by 1% due to a high tax rate of 39%.
Lupin is a BUY at CMP@1470 with SL@1420 for a target of TP@1600
การซื้อขายยังคงดำเนินอยู่:
Trade Activated @1473.00 for a Target of 1600 with SL 1420.
ปิดการเทรด: ถึงเป้าหมายการทำกำไร:
The Pharma sector seems to be weak and recently Divis had problems on USFDA Approvals , So use this rally to exit in LUPIN as we can enter later at a lower price. Buy initiated @1470 Lupin closed @ 1490 for a profit of 20. #SB7